BioCryst Pharmaceuticals (BCRX) reported Friday preliminary Q4 revenue of $130.8 million, up 40% year over year.
Analysts polled by FactSet expected $128.6 million.
The company said it expects full-year 2025 revenue between $540 million and $560 million. Analysts polled by FactSet expect $536.4 million.
Shares of the company fell 4.5% in recent trading.
Price: 7.69, Change: -0.36, Percent Change: -4.47
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。